PMID- 11332992
OWN - NLM
STAT- MEDLINE
DCOM- 20011101
LR  - 20081121
IS  - 0929-1903 (Print)
IS  - 0929-1903 (Linking)
VI  - 8
IP  - 3
DP  - 2001 Mar
TI  - Transfection of dendritic cells (DCs) with the CIITA gene: increase in 
      immunostimulatory activity of DCs.
PG  - 211-9
AB  - Dendritic cells (DCs) are the major antigen-presenting cells. They are able to 
      present tumor antigens to immunologic effector cells. MHC class II molecules on 
      DC surfaces play an important role in priming effector cells against tumor cells 
      and their antigens. The transactivator CIITA (MHC class II transactivator) is a 
      non-DNA-binding transactivator, which regulates the expression of MHC class II, 
      HLA-DM, and invariant chain and behaves as a master controller of constitutive 
      and inducible MHC class II gene activation. Here, we transfected DCs with the 
      CIITA gene using a novel transfection technique. The vector system consisted of a 
      plasmid bound to an adenovirus via poly-L-lysine, which is covalently bound to a 
      UV-irradiated adenovirus. After transfection, expression of MHC class II on DCs 
      increased from 27% to 75% on day 2 after transfection. Transfected DCs were 
      co-cultured with immunologic effector cells. Cytotoxicity of effector cells 
      against tumor cells increased after co-culture with transfected DCs to 63% 
      compared to 15% with effector cells co-cultured with irrelevantly transfected DCs 
      (P=.037). This effect was dependent on the timing and period of co-culture. In 
      conclusion, transfection of DCs led to an increase in antitumoral 
      immunostimulatory capacity of DCs. We can further conclude that DCs could be 
      efficiently transfected with the CIITA gene. Transfection of DCs led to an 
      increase in antitumoral immunostimulatory capacity of DCs and may have a major 
      impact on immunotherapeutic protocols for patients with cancer.
FAU - Marten, A
AU  - Marten A
AD  - Medizinische Klinik und Poliklinik I, Rheinische Friedrich-Wilhelms-Universitat, 
      Bonn, Germany.
FAU - Ziske, C
AU  - Ziske C
FAU - Schottker, B
AU  - Schottker B
FAU - Weineck, S
AU  - Weineck S
FAU - Renoth, S
AU  - Renoth S
FAU - Buttgereit, P
AU  - Buttgereit P
FAU - Schakowski, F
AU  - Schakowski F
FAU - Konig, S
AU  - Konig S
FAU - von Rucker, A
AU  - von Rucker A
FAU - Allera, A
AU  - Allera A
FAU - Schroers, R
AU  - Schroers R
FAU - Sauerbruch, T
AU  - Sauerbruch T
FAU - Wittig, B
AU  - Wittig B
FAU - Schmidt-Wolf, I G
AU  - Schmidt-Wolf IG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cancer Gene Ther
JT  - Cancer gene therapy
JID - 9432230
RN  - 0 (Ligands)
RN  - 0 (MHC class II transactivator protein)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Trans-Activators)
RN  - 25104-18-1 (Polylysine)
SB  - IM
MH  - Adenoviridae/metabolism
MH  - Carcinoma/immunology
MH  - Colonic Neoplasms/immunology
MH  - Dendritic Cells/*immunology
MH  - Gene Expression Regulation
MH  - Genes, MHC Class II/genetics/immunology
MH  - Genetic Vectors
MH  - Humans
MH  - Immunization
MH  - Ligands
MH  - *Nuclear Proteins
MH  - Pancreatic Neoplasms/immunology
MH  - Polylysine/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Trans-Activators/*genetics
MH  - Transcriptional Activation
MH  - Transfection/*methods
MH  - Tumor Cells, Cultured
EDAT- 2001/05/03 10:00
MHDA- 2001/11/03 10:01
CRDT- 2001/05/03 10:00
PHST- 2001/05/03 10:00 [pubmed]
PHST- 2001/11/03 10:01 [medline]
PHST- 2001/05/03 10:00 [entrez]
AID - 10.1038/sj.cgt.7700292 [doi]
PST - ppublish
SO  - Cancer Gene Ther. 2001 Mar;8(3):211-9. doi: 10.1038/sj.cgt.7700292.